Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer

BACKGROUND: In a phase II North American study (NP28761; NCT01871805), the anaplastic lymphoma kinase (ALK) inhibitor alectinib demonstrated both systemic and central nervous system (CNS) efficacy with good tolerability in patients with ALK-positive non-small cell lung cancer. We describe patient-re...

Descripción completa

Detalles Bibliográficos
Autores principales: Ou, Sai-Hong Ignatius, Socinski, Mark A, Gadgeel, Shirish, Gandhi, Leena, West, Howard, Chiappori, Alberto Alejandro, Cohen, Victor, Riely, Gregory J, Smoljanovic, Vlatka, Bordogna, Walter, Wright, Elaine, Debusk, Kendra, Zeaiter, Ali, Shaw, Alice T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6045737/
https://www.ncbi.nlm.nih.gov/pubmed/30018815
http://dx.doi.org/10.1136/esmoopen-2018-000364

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6045737/
https://www.ncbi.nlm.nih.gov/pubmed/30018815
http://dx.doi.org/10.1136/esmoopen-2018-000364

Ejemplares similares